RU2745069C2 - Спироциклические соединения - Google Patents

Спироциклические соединения Download PDF

Info

Publication number
RU2745069C2
RU2745069C2 RU2017133973A RU2017133973A RU2745069C2 RU 2745069 C2 RU2745069 C2 RU 2745069C2 RU 2017133973 A RU2017133973 A RU 2017133973A RU 2017133973 A RU2017133973 A RU 2017133973A RU 2745069 C2 RU2745069 C2 RU 2745069C2
Authority
RU
Russia
Prior art keywords
cancer
optionally substituted
mmol
compound
alkyl
Prior art date
Application number
RU2017133973A
Other languages
English (en)
Russian (ru)
Other versions
RU2017133973A3 (enExample
RU2017133973A (ru
Inventor
Питер Циньхуа ХУАН
Мехмет Кахраман
Дебора Хелен СЛИ
Кевин Дуэйн БАНКЕР
Чад Дэниэл ХОПКИНС
Джозеф Роберт ПИНЧМАН
Санни Абрахам
Ракеш Кумар СИТ
Дэниэл Ли СЕВЕРАНС
Original Assignee
РЕКЬЮРИУМ АйПи ХОЛДИНГС, ЛЛС
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by РЕКЬЮРИУМ АйПи ХОЛДИНГС, ЛЛС filed Critical РЕКЬЮРИУМ АйПи ХОЛДИНГС, ЛЛС
Publication of RU2017133973A publication Critical patent/RU2017133973A/ru
Publication of RU2017133973A3 publication Critical patent/RU2017133973A3/ru
Application granted granted Critical
Publication of RU2745069C2 publication Critical patent/RU2745069C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
RU2017133973A 2015-04-03 2016-03-31 Спироциклические соединения RU2745069C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562142946P 2015-04-03 2015-04-03
US62/142,946 2015-04-03
PCT/US2016/025345 WO2016161160A1 (en) 2015-04-03 2016-03-31 Spirocyclic compounds

Publications (3)

Publication Number Publication Date
RU2017133973A RU2017133973A (ru) 2019-05-06
RU2017133973A3 RU2017133973A3 (enExample) 2019-07-17
RU2745069C2 true RU2745069C2 (ru) 2021-03-18

Family

ID=57007413

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017133973A RU2745069C2 (ru) 2015-04-03 2016-03-31 Спироциклические соединения

Country Status (25)

Country Link
US (3) US10525036B2 (enExample)
EP (1) EP3277690B1 (enExample)
JP (1) JP6737533B2 (enExample)
KR (1) KR20170132307A (enExample)
CN (1) CN107849053B (enExample)
AU (1) AU2016242940B2 (enExample)
BR (1) BR112017021194A2 (enExample)
CA (1) CA2981055A1 (enExample)
CY (1) CY1123019T1 (enExample)
DK (1) DK3277690T3 (enExample)
ES (1) ES2788160T3 (enExample)
HR (1) HRP20200805T1 (enExample)
HU (1) HUE049481T2 (enExample)
IL (1) IL254662B (enExample)
LT (1) LT3277690T (enExample)
MX (1) MX379622B (enExample)
PL (1) PL3277690T3 (enExample)
PT (1) PT3277690T (enExample)
RS (1) RS60340B1 (enExample)
RU (1) RU2745069C2 (enExample)
SG (1) SG11201707911VA (enExample)
SI (1) SI3277690T1 (enExample)
SM (1) SMT202000279T1 (enExample)
TW (1) TWI705067B (enExample)
WO (1) WO2016161160A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106999451B (zh) * 2014-09-17 2021-04-02 里科瑞尔姆Ip控股有限责任公司 双环化合物
EP3277690B1 (en) 2015-04-03 2020-02-26 Recurium IP Holdings, LLC Spirocyclic compounds
KR20190075931A (ko) 2016-10-05 2019-07-01 제노 로얄티즈 앤 마일스톤즈, 엘엘씨 스피로 고리 화합물
CA3045947A1 (en) * 2016-12-08 2018-06-14 Michael J. Soth Bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (dlk) kinase for the treatment of disease
JP2021512109A (ja) * 2018-01-31 2021-05-13 アプティニックス インコーポレイテッド スピロラクタム系ｎｍｄａ受容体修飾因子およびその使用
EP3956330A4 (en) 2019-04-18 2023-01-18 The Johns Hopkins University SUBSTITUTED 2-AMINO-PYRAZOLYL-[1,2,4]TRIAZOLO[1,5A]PYRIDINE DERIVATIVES AND THEIR USE
US11560366B2 (en) 2019-10-21 2023-01-24 Board Of Regents, The University Of Texas System Bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (DLK) kinase for the treatment of disease
IL301817A (en) 2020-10-13 2023-06-01 Univ Johns Hopkins Modified 4-([4,2,1]triazolo[5,1-a]pyridin-6-yl)thiophene-2-carboxamide histories and their use
CN115124542A (zh) * 2022-07-08 2022-09-30 河南师范大学 羟基苯取代吡唑酮并吲唑[螺]吡唑酮类化合物的合成方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090118284A1 (en) * 2005-12-13 2009-05-07 Cooper Alan B Novel compounds that are ERK inhibitors
WO2011041152A1 (en) * 2009-09-30 2011-04-07 Schering Corporation Novel compounds that are erk inhibitors
US20140135335A1 (en) * 2012-11-09 2014-05-15 Bristol-Myers Squibb Company Spiro bicyclic oxalamide compounds for the treatment of hepatitis c
RU2525389C2 (ru) * 2008-02-21 2014-08-10 Мерк Шарп И Доум Корп. Соединения, которые являются ингибиторами erk
WO2014149819A1 (en) * 2013-03-14 2014-09-25 Kalyra Pharmaceuticals, Inc. Bicyclic analgesic compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR057579A1 (es) * 2005-11-23 2007-12-05 Merck & Co Inc Compuestos espirociclicos como inhibidores de histona de acetilasa (hdac)
JP5380296B2 (ja) 2006-11-17 2014-01-08 ポリエラ コーポレイション ジイミド系半導体材料ならびにジイミド系半導体材料を調製および使用する方法
EP2318388A2 (en) 2008-07-23 2011-05-11 Schering Corporation Tricyclic spirocycle derivatives and methods of use thereof
CA3044884A1 (en) 2009-12-07 2011-06-16 Arbutus Biopharma Corporation Compositions for nucleic acid delivery
WO2013033059A1 (en) 2011-08-29 2013-03-07 Bristol-Myers Squibb Company Spiro bicyclic diamine derivatives as hiv attachment inhibitors
CN103130775B (zh) * 2011-11-22 2015-09-30 山东亨利医药科技有限责任公司 作为酪氨酸激酶抑制剂的吲哚满酮衍生物
CN105732636B (zh) 2014-12-30 2020-04-21 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用
EP3277690B1 (en) 2015-04-03 2020-02-26 Recurium IP Holdings, LLC Spirocyclic compounds
KR20190075931A (ko) 2016-10-05 2019-07-01 제노 로얄티즈 앤 마일스톤즈, 엘엘씨 스피로 고리 화합물

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090118284A1 (en) * 2005-12-13 2009-05-07 Cooper Alan B Novel compounds that are ERK inhibitors
RU2525389C2 (ru) * 2008-02-21 2014-08-10 Мерк Шарп И Доум Корп. Соединения, которые являются ингибиторами erk
WO2011041152A1 (en) * 2009-09-30 2011-04-07 Schering Corporation Novel compounds that are erk inhibitors
US20140135335A1 (en) * 2012-11-09 2014-05-15 Bristol-Myers Squibb Company Spiro bicyclic oxalamide compounds for the treatment of hepatitis c
WO2014149819A1 (en) * 2013-03-14 2014-09-25 Kalyra Pharmaceuticals, Inc. Bicyclic analgesic compounds

Also Published As

Publication number Publication date
RU2017133973A3 (enExample) 2019-07-17
CA2981055A1 (en) 2016-10-06
JP2018511613A (ja) 2018-04-26
BR112017021194A2 (pt) 2019-01-08
PL3277690T3 (pl) 2020-08-24
MX2017012553A (es) 2018-04-11
AU2016242940A1 (en) 2017-10-26
CY1123019T1 (el) 2021-10-29
SG11201707911VA (en) 2017-10-30
RU2017133973A (ru) 2019-05-06
US10525036B2 (en) 2020-01-07
PT3277690T (pt) 2020-03-24
HK1256671A1 (en) 2019-09-27
IL254662A0 (en) 2017-11-30
ES2788160T3 (es) 2020-10-20
AU2016242940B2 (en) 2020-11-05
HRP20200805T1 (hr) 2020-10-16
US20190201380A1 (en) 2019-07-04
DK3277690T3 (da) 2020-05-04
LT3277690T (lt) 2020-06-10
JP6737533B2 (ja) 2020-08-12
WO2016161160A1 (en) 2016-10-06
TWI705067B (zh) 2020-09-21
SMT202000279T1 (it) 2020-07-08
US20180207132A1 (en) 2018-07-26
US20200268714A1 (en) 2020-08-27
KR20170132307A (ko) 2017-12-01
RS60340B1 (sr) 2020-07-31
EP3277690B1 (en) 2020-02-26
MX379622B (es) 2025-03-11
CN107849053B (zh) 2020-10-30
SI3277690T1 (sl) 2020-07-31
IL254662B (en) 2021-02-28
TW201710261A (zh) 2017-03-16
EP3277690A4 (en) 2018-08-22
HUE049481T2 (hu) 2020-09-28
CN107849053A (zh) 2018-03-27
US10493060B2 (en) 2019-12-03
EP3277690A1 (en) 2018-02-07

Similar Documents

Publication Publication Date Title
US10934304B2 (en) Spirocyclic compounds
US10493060B2 (en) Spirocyclic compounds
KR102645995B1 (ko) Rsv 억제제로서의 병용 약학 제제
JP7112324B2 (ja) Ｒｓｖ阻害剤としてのベンゾジアゼピン誘導体
KR102398473B1 (ko) Tam 패밀리 키나제 억제제로서의 아미노피리딘 유도체
TW202241906A (zh) 吲唑化合物
EP4153582B1 (en) Piperazine cyclic ureas
US20210292305A1 (en) Cyclic Ureas
EP4570319A2 (en) Brm targeting compounds and associated methods of use
ES3015269T3 (en) Indazolyl-isoxazole derivatives for the treatment of diseases such as cancer
WO2023049199A1 (en) Azole compounds
HK1256671B (en) Spirocyclic compounds
NZ751398B2 (en) Spirocyclic compounds

Legal Events

Date Code Title Description
HZ9A Changing address for correspondence with an applicant